严重喘生物治疗的成本效益结果的决定因素:系统的方法评估
Laura de la Torre-Pérez1, Marilina Santero1, Wendy Nieto-Gutierrez2
1Methodology of Biomedical Research and Public Health PhD Program, Universitat Autónoma de Barcelona, Barcelona, Spain; Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, Barcelona 08041, Spain; Centro Cochrane Iberoamericano, Sant Antoni Maria Claret, 167, Barcelona 08025, Spain.
Journal of clinical epidemiology
|December 5, 2024
概括
产业赞助对喘生物制品的成本效益分析 (CEA) 结论产生重大影响. 非行业赞助的研究更有可能报告药物不具有成本效益,突出了经济评估中的潜在偏见.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 临床研究方法论 临床研究方法论
背景情况:
- 成本效益分析 (CEA) 对于评估严重喘的生物治疗非常重要.
- CEA的方法特征可以影响其结果和结论.
- 了解这些关联对于基于证据的医疗保健决策至关重要.
研究的目的:
- 评估CEA的方法特征及其报告的增量成本效益比率 (ICER) 结果和结论之间的关系.
- 特别关注生物喘治疗的经济评估.
主要方法:
- 在MEDLINE,EMBASE和Web of Science的系统文献搜索中,寻找生物喘治疗的CEA.
- 使用扩展的共识健康经济标准提取和批判性评估CEA的方法特征.
- 对28项成本效益分析进行了双变量和回归分析,重点关注质量调整后寿命年 (QALY).
主要成果:
- 确定了33个CEA,通常表现出良好的质量,但对标准的坚持有变化.
- 工业赞助与ICER中位数的差异显著相关,并报告了成本效益.
- 非行业赞助与被报告为不具有成本效益的药物 (ORs > 13) 有着强烈的关联.
结论:
- 喘生物制剂CEA的重大局限性包括报告不足和行业赞助的影响.
- 决策者必须仔细考虑方法论的严谨性和潜在的偏见,特别是赞助.
- 这些发现强调了经济评估需要透明度和批判性评估的必要性.
相关概念视频
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
238
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
238
01:19Antiasthma Drugs: Leukotriene Modifiers
252
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
252
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
227
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
227
01:17Drugs Used in Lower Respiratory Disorders: Overview
360
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
360
01:26COPD: Management Using Bronchodilators and Corticosteroids
186
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
186
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
245
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
245